PAK4 overexpression
|
Solid Tumor
|
PAK4 overexpression
|
Solid Tumor
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PAK4 overexpression
|
Melanoma
|
PAK4 overexpression
|
Melanoma
|
vemurafenib Resistant: D – Preclinical
|
vemurafenib Resistant: D – Preclinical
|
PAK4 overexpression
|
Solid Tumor
|
PAK4 overexpression
|
Solid Tumor
|
KPT-9274 + PD1 inhibitor Sensitive: D – Preclinical
|
KPT-9274 + PD1 inhibitor Sensitive: D – Preclinical
|